Skip to main content

Table 2 Subgroup analyses for the association between PS and the survival

From: Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis

Subgroup analysis

OS

PFS

No. of studies

Pooled HR (95% CI)

P value

Heterogeneity

No. of studies

Pooled HR (95% CI)

P value

Heterogeneity

I2 (%)

P

I2 (%)

P

Overall

17

2.08 (1.78–2.45)

<  0.00001

8

0.36

8

1.51 (1.20–1.91)

0.0005

25

0.23

Type of PS scale

 KPS

6

2.20 (1.65–2.94)

<  0.00001

24

0.26

5

1.74 (1.19–2.56)

0.005

0

0.50

 ECOG PS

11

2.03 (1.68–2.46)

<  0.00001

6

0.39

3

1.39 (1.04–1.87)

0.03

61

0.08

Study setting

 Asia

6

2.25 (1.71–2.95)

<  0.00001

26

0.24

4

1.73 (1.14–2.64)

0.01

11

0.34

 Europe

8

1.95 (1.56–2.43)

<  0.00001

28

0.20

4

1.42 (1.08–1.88)

0.01

44

0.15

 America

3

2.25 (1.43–3.53)

0.0005

0

0.93

0

Year of publication

 Before 2015

11

1.79 (1.44–2.22)

<  0.00001

17

0.28

6

1.51 (1.18–1.94)

0.001

44

0.11

 After 2015

6

2.49 (1.97–3.15)

<  0.00001

0

0.95

2

1.50 (0.73–3.07)

0.27

0

0.56

NOS score

 6

5

2.07 (1.57–2.74)

<  0.00001

28

0.24

2

0.90 (0.54–1.50)

0.67

40

0.20

 7

7

1.80 (1.40–2.32)

<  0.00001

19

0.29

4

1.57 (1.18–2.10)

0.002

0

0.92

 8

5

2.61 (1.92–3.55)

<  0.00001

0

0.90

2

2.43 (1.36–4.33)

0.003

0

0.43

  1. OS overall survival, PFS progression-free survival, PS performance status, KPS Karnofsky performance status, ECOG PS Eastern Cooperative Oncology Group performance status, NOS Newcastle-Ottawa score, CI confidence interval